Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Motley Fool Asset Management LLC

Motley Fool Asset Management LLC reduced its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 8.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,035 shares of the biopharmaceutical company’s stock after selling 196 shares during the period. Motley […]

Related Keywords

,Motley Fool Asset Management ,News Ratings For Alnylam Pharmaceuticals Daily ,Wells Fargo Company ,Raymond James Associates ,S Capital Wealth Advisors ,Jpmorgan Chase Co ,Alnylam Pharmaceuticals Stock Performance ,Quarter For Alnylam Pharmaceuticals ,Exchange Commission ,Alnylam Pharmaceuticals Inc ,Harbor Capital Advisors Inc ,Commonwealth Equity Services ,Alnylam Pharmaceuticals Profile ,Alnylam Pharmaceuticals ,Wolfe Research ,Xponance Inc ,Cantor Fitzgerald ,Nasdaq ,Free Report ,Fool Asset Management ,Wealth Advisors ,Capital Advisors ,Equity Services ,Raymond James ,Get Free Report ,Visit Holdingschannel ,Alnylam Pharmaceuticals Daily ,Nasdaq Alny ,Dalny ,Medical ,02043q10 ,Sec Filings ,13f ,Hedge Fund Holdings ,Institutional Investor Holdings ,